Clinical Trial Update: Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy of rechallenge with sunitinib in metastatic pancreatic neuroendocrine tumor that previously failed sunitinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Pancreatic Neuroendocrine Tumour Metastatic | Phase 2 | Status: COMPLETED